The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

Similarly, tirzepatide has been approved for type 2 diabetes under the name Mounjaro and for obesity under the name Zepbound (or Mounjaro in some regions). On 20 December, tirzepatide also ...

Some of the biggest highlights from obesity studies in 2024 included new data on semaglutide and tirzepatide, as well as a new study on risks with sarcopenia. Image: Adobe Stock SURMOUNT-OSA ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Tirzepatide does not yield a significant increase in pancreatitis risk despite elevating pancreatic enzyme levels, according to study findings published in Obesity Science and Practice. Tirzepatide, a ...